470 related articles for article (PubMed ID: 31158837)
1. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
Spooner K; Hong T; Fraser-Bell S; Chang AA
Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept.
Spooner K; Hong T; Bahrami B; Chang A
Acta Ophthalmol; 2019 Feb; 97(1):15-23. PubMed ID: 30251325
[TBL] [Abstract][Full Text] [Related]
6. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.
Sangroongruangsri S; Ratanapakorn T; Wu O; Anothaisintawee T; Chaikledkaew U
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):903-916. PubMed ID: 30071180
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
10. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusions: A Systematic Review and Meta-Analysis.
Spooner K; Hong T; Fraser-Bell S; Chang A
Asia Pac J Ophthalmol (Phila); 2019; 8(3):236-246. PubMed ID: 31132002
[TBL] [Abstract][Full Text] [Related]
11. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
12. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
[TBL] [Abstract][Full Text] [Related]
18. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
[TBL] [Abstract][Full Text] [Related]
20. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
